Skip to content
ClinCalc Pro
Menu
Cystic Fibrosis

Sodium Chloride 7% (Hypertonic Saline)

Brand names: HyperSal, MucoClear 7%

Nebulised hypertonic sodium chloride 7% is a mucoactive agent used to improve airway clearance, principally in cystic fibrosis and some other suppurative lung conditions. It is delivered by jet or mesh nebuliser, not given systemically.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

The hyperosmolar solution draws water onto the airway surface, rehydrating the periciliary layer, reducing mucus viscosity and improving mucociliary and cough clearance.

Prescribing in practice

  • Inhalation commonly provokes bronchospasm, cough and chest tightness, so a test dose should be supervised and a bronchodilator given beforehand in those at risk.
  • Where co-prescribed with inhaled dornase alfa or antibiotics, separate the nebulised treatments and follow a logical airway-clearance order rather than mixing solutions.
  • Pre-treatment with a short-acting bronchodilator before each dose is advised where airway reactivity is a concern.

Monitoring

Monitor tolerability of the first supervised dose with assessment of bronchospasm and, where indicated, spirometry before and after inhalation.

Counselling the patient

  • Use a bronchodilator beforehand if advised and stop if you develop marked wheeze or breathlessness.
  • Clean and dry the nebuliser after every use to reduce infection risk.

Evidence & guidelines

Nebulised hypertonic saline is supported by cystic fibrosis trial evidence and NICE/CF guidance showing improved clearance and modest lung-function benefit.

Reference: CFFT Trial (Elkins et al. NEJM 2006); NICE NG78 CF Guidelines; SPC MucoClear 7%; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.